ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck, Bionomics In Alzheimer’s Pact

by Rick Mullin
July 7, 2014 | APPEARED IN VOLUME 92, ISSUE 27

Bionomics, an Australian small-molecule drug discovery firm, has licensed to Merck & Co. its BNC375 research program targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system disorders. Merck will fund all R&D and will commercialize any resulting products. Bionomics will receive $20 million up front and is eligible for up to $506 million in milestone payments. The two companies signed a similar agreement last year around pain treatments.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment